Journal article
Non-Animal Stabilized Hyaluronic Acid/Dextranomer Gel (NASHA/Dx, Deflux) for Endoscopic Treatment of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?
Urology (Ridgewood, N.J.), Vol.157, pp.15-28
11/2021
DOI: 10.1016/j.urology.2021.07.032
PMID: 34411597
Abstract
Non-animal stabilized hyaluronic acid/dextranomer gel (Deflux; NASHA/Dx) was developed as a treatment for vesicoureteral reflux (VUR) in the 1990s. To mark 20 years since the US approval of this agent, we reviewed its properties, best practice for application, and the available clinical safety and efficacy data. Long-term or randomized, controlled studies of treatment with NASHA/Dx have reported VUR resolution rates of 59%-100% with low rates of febrile urinary tract infection post-treatment (4%-25%), indicating long-term protection of the kidneys. An individualized approach VUR management is advocated, and NASHA/Dx is a viable option for many patients requiring intervention.
Details
- Title: Subtitle
- Non-Animal Stabilized Hyaluronic Acid/Dextranomer Gel (NASHA/Dx, Deflux) for Endoscopic Treatment of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?
- Creators
- Andrew J Kirsch - Children's Healthcare of AtlantaChristopher S Cooper - University of IowaGöran Läckgren - Boston Children's Hospital
- Resource Type
- Journal article
- Publication Details
- Urology (Ridgewood, N.J.), Vol.157, pp.15-28
- DOI
- 10.1016/j.urology.2021.07.032
- PMID
- 34411597
- NLM abbreviation
- Urology
- ISSN
- 0090-4295
- eISSN
- 1527-9995
- Language
- English
- Date published
- 11/2021
- Academic Unit
- Stead Family Department of Pediatrics; Urology; Medicine Administration
- Record Identifier
- 9984319987402771
Metrics
14 Record Views